logo
India among top suppliers of illicit fentanyl precursors, US intelligence report says

India among top suppliers of illicit fentanyl precursors, US intelligence report says

CNN28-03-2025

India has emerged as a growing player in the illicit fentanyl trade, a new US intelligence report says, a designation likely to raise alarm in New Delhi as President Donald Trump wields tariffs on countries he accuses of not doing enough to stop the deadly drug from flowing into the United States.
Fentanyl, a powerful synthetic opioid that can be 100 times more potent than morphine, is the most common drug involved in overdose deaths in the US – fueling an opioid crisis that has become a high-priority issue for the Trump administration.
For many years, China has been the largest source of both legal supplies of the drug – which is prescribed for severe pain relief – and illicit supplies of precursor chemicals that are typically processed in labs in Mexico before the final product is smuggled across the US border.
But India's role in the illegal trade is becoming more prominent, according to the 2025 Annual Threat Assessment (ATA) report published by the Office of the Director of National Intelligence this month.
'Nonstate groups are often enabled, both directly and indirectly, by state actors, such as China and India as sources of precursors and equipment for drug traffickers,' the report said.
'China remains the primary source country for illicit fentanyl precursor chemicals and pill pressing equipment, followed by India.'
Last year's ATA report named India as among countries other than China where Mexican cartels were sourcing precursor chemicals to a 'lesser extent.' The 2023 report made no mention of India in relation to fentanyl.
India is a global leader in generic drug manufacturing, supplying a significant portion of the world's vaccines and medicines. It has a pharmaceutical industry so large, it is often referred to as the 'Pharmacy of the World.' But the industry has been marred by controversy, raising concerns about regulation and quality control.
On March 17, India's Anti-Terrorist Squad (ATS) in the western state of Gujarat said it had arrested two people linked to Surat-based pharmaceutical companies for allegedly exporting illicit fentanyl precursors to Mexico and Guatemala, according to the Press Trust of India. CNN has reached out to the ATS.
Days later, the US Department of Justice indicted three top executives from a Hyderabad-based pharmaceutical company for allegedly importing ingredients used to make illicit fentanyl.
New Delhi has not publicly spoken about the ATA report. CNN has contacted India's Ministry of External Affairs for a response.
The report comes at a delicate time for India as it mounts a case to avoid US tariffs.
The US was India's largest trading partner in 2024, accounting for almost $120 billion in trade, yet India only ranked tenth in the list of US trading partners for the same year.
Indian economist and researcher Soumya Bhowmik said the ATA report 'may introduce complexities in India-US relations,' and could 'open the door for tougher rhetoric and potentially even targeted tariffs.'
Earlier this month, the Trump administration enacted tariffs against the US' top three trading partners: China, Mexico and Canada, saying the levies of up to 25% were necessary to stem the flow of fentanyl into the US.
Indian Prime Minister Narendra Modi visited Washington in February, where he spoke with Trump about a range of issues from defense and technology to trade and economic growth.
The two leaders 'resolved to expand trade and investment to make their citizens more prosperous, nations stronger, economies more innovative and supply chains more resilient,' a joint statement from that meeting said.
A Washington delegation is currently in New Delhi for trade talks.
India has 'proactively undertaken measures to respond to potential trade tensions and mitigate the impact of impending US tariffs,' said Bhowmik, including a proposal to remove import duties on goods essential for manufacturing.
The ATA report also 'highlights the critical importance of collaborative efforts between (the US and India) to address the global opioid crisis,' Bhowmik said.

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment
FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment

Yahoo

time9 minutes ago

  • Yahoo

FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment

The US Food and Drug Administration (FDA) has granted 510(k) clearance to Neurent Medical's NEUROMARK system for the treatment of individuals with chronic rhinitis. Comprising a single-use, handheld bipolar radiofrequency (RF) device and a reusable console with a graphical user interface, the system is designed to conform to the anatomy of the patient and target nerve-rich regions in the nasal cavity. Its bioimpedance monitoring technology adjusts energy delivery based on the changes in tissue conductivity. This method makes sure treatment is precise by continuously evaluating the conditions of the tissue and adjusting energy flow, thereby increasing therapeutic outcomes. According to the company, the system's real-time feedback and smart algorithmic control are crucial for directing the proper placement of the electrode and ensuring treatment delivery success. Its atraumatic leaflets and flexible haft will aid physicians in accessing challenging nasal cavity areas and increase the treatment coverage, along with the posterior areas of the lateral nasal wall. The system claims to operate by delivering impedance-controlled, low-power RF energy to disrupt parasympathetic nerve signals. This addresses the primary symptoms of chronic rhinitis, which include rhinorrhoea (runny nose) and persistent congestion in the nasal area. With the FDA clearance, the system is set for broader availability in the US market. The Ireland-based company focuses on chronic inflammatory sino-nasal disease treatments. Neurent Medical CEO Brian Shields said: 'We have just completed a highly successful commercial validation phase, positioning the NEUROMARK system at the forefront of chronic rhinitis care. 'During this phase, we collaborated with leading General ENT [ear, nose, and throat] and rhinology specialists across both private practice and academic settings. Their insights were instrumental in shaping this next-generation system. I am incredibly proud of how their feedback translated into meaningful technological improvements.' "FDA clears Neurent Medical's NEUROMARK for chronic rhinitis treatment" was originally created and published by Medical Device Network, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site. Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data

Corti launches new FactsR system for clinical consultations
Corti launches new FactsR system for clinical consultations

Yahoo

time9 minutes ago

  • Yahoo

Corti launches new FactsR system for clinical consultations

Healthcare technology company Corti has introduced FactsR, a real-time agentic reasoning system designed for clinical consultations. This system aims to lessen 'note bloat' driven by general-purpose AI by 65%, ensuring that medical records remain precise and relevant to the actual clinical conversation. FactsR stands out from traditional large language model (LLM) pipelines adapted for healthcare by utilising Corti's recursive fact-first reasoning loop. By minimising the need for post-visit edits and transforming passive transcripts into active clinical intelligence, FactsR paves the way for real-time decision support directly at the point of care. Offered as a modular API, the system enables developers to integrate clinical-grade intelligence into healthcare applications, fostering safer AI experiences. It allows for the creation of AI that delivers concise and accurate results, which clinicians can interact with during consultations. FactsR operates in four key areas. Firstly, it listens and extracts structured clinical facts in real-time, such as symptoms and medications, during the consultation. Secondly, each fact is vetted and refined through a specialised AI-driven feedback loop, ensuring accuracy and consistency. Later on, clinicians have the opportunity to review and adjust the facts, maintaining control and complementing clinical judgement. Lastly, the system generates electronic health record (EHR)-ready notes that are concise and free from irrelevant content, leading to reduced screen time and improved focus on the patient. chief technology officer and co-founder Lars Maaløesaid: 'By breaking conversations into structured clinical facts and validating each one through recursive reasoning, FactsR elevates ambient documentation into a foundation for real-time clinical intelligence. 'When AI can listen, understand, and reason with medical context, it becomes more than a scribe - it becomes a trusted collaborator. With a developer-friendly API, we're enabling any healthtech company to embed this capability directly into their applications - safely, scalably, and in minutes.' In October 2024, Corti announced a collaboration with US-based Tanner Health and its subsidiary Healthliant Ventures. "Corti launches new FactsR system for clinical consultations" was originally created and published by Hospital Management, a GlobalData owned brand. The information on this site has been included in good faith for general informational purposes only. It is not intended to amount to advice on which you should rely, and we give no representation, warranty or guarantee, whether express or implied as to its accuracy or completeness. You must obtain professional or specialist advice before taking, or refraining from, any action on the basis of the content on our site.

Trump administration sues New York over law barring warrantless immigration arrests at courthouses
Trump administration sues New York over law barring warrantless immigration arrests at courthouses

Hamilton Spectator

time10 minutes ago

  • Hamilton Spectator

Trump administration sues New York over law barring warrantless immigration arrests at courthouses

ALBANY, N.Y. (AP) — The Trump administration sued New York state Thursday over a law that blocks immigration officials from arresting people at New York courthouses, saying it purposely shields dangerous criminals. The lawsuit in New York's Northern District is the latest in a series of legal actions targeting state or local policies the administration says interfere with immigration enforcement, authorities said. 'Lawless sanctuary city policies are the root cause of the violence that Americans have seen in California, and New York State is similarly employing sanctuary city policies to prevent illegal aliens from apprehension,' U.S. Attorney General Pamela Bondi said in a news release. New York's 2020 Protect Our Courts Act bans federal immigration officials from arresting people who are coming and going from courthouses or in court for proceedings unless they have a warrant signed by a judge. Democratic state Sen. Brad Hoylman , the bill's sponsor, said at the time the legislation was a rebuke to the first Trump administration's practice of turning New York courts into 'hunting grounds' for federal agents. The Justice Department's lawsuit said arrests in or near courthouses are safer for officers and the public because individuals are screened for weapons and contraband before entering the buildings. Emails seeking comment were sent to New York Gov. Kathy Hochul's office and Hoylman. Hochul is among a group of Democratic governors in Washington on Thursday to face questioning from Congress over policies limiting cooperation with federal immigration authorities. Error! Sorry, there was an error processing your request. There was a problem with the recaptcha. Please try again. You may unsubscribe at any time. By signing up, you agree to our terms of use and privacy policy . This site is protected by reCAPTCHA and the Google privacy policy and terms of service apply. Want more of the latest from us? Sign up for more at our newsletter page .

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store